Streamlining market access to advanced therapies: What can we learn from global models?
Tracks
Track 3
| Friday, November 1, 2024 |
| 10:30 AM - 11:15 AM |
| Room 110 |
Details
Around the world there are different approaches to health technology assessment, regulatory approvals and reimbursement pathways. Streamlining market access for cell and gene therapies is essential and Australia’s current systems were not established for these advanced therapies. This session will ask what Australia can learn from models around the world. Sustainable market access pathways will accelerate the cell and gene industry’s growth, enable health system readiness, create job opportunities and ensure everyone in Australia has access to these advanced therapies.
Speaker
Dr. Jane Adams
Associate Director Market Access
Novartis
Panellist
Dr. Gretchen Poortinga
Program Operations Director, Centre of Excellence in Cellular Immunotherapy
Peter MacCallum Cancer Centre
Panellist
Mr Warwick Shaw
Market Access Cell & Gene Therapies and Medicines Australia Rare Diseases Working Group
Johnson & Johnson
Chair
